Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Non-Current Deffered Revenue (2016 - 2026)

Tandem Diabetes Care filings provide 11 years of Non-Current Deffered Revenue readings, the most recent being $8.5 million for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue fell 18.95% to $8.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.5 million, a 18.95% decrease, with the full-year FY2025 number at $8.5 million, down 18.95% from a year prior.
  • Non-Current Deffered Revenue hit $8.5 million in Q4 2025 for Tandem Diabetes Care, down from $8.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $19.1 million in Q3 2022 to a low of $8.5 million in Q4 2025.
  • Median Non-Current Deffered Revenue over the past 5 years was $13.3 million (2023), compared with a mean of $13.5 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: fell 0.39% in 2022 and later fell 26.4% in 2023.
  • Tandem Diabetes Care's Non-Current Deffered Revenue stood at $16.9 million in 2021, then decreased by 0.39% to $16.9 million in 2022, then fell by 21.0% to $13.3 million in 2023, then dropped by 21.57% to $10.5 million in 2024, then dropped by 18.95% to $8.5 million in 2025.
  • The last three reported values for Non-Current Deffered Revenue were $8.5 million (Q4 2025), $8.8 million (Q3 2025), and $9.6 million (Q2 2025) per Business Quant data.